Zoeken
  • non-viral drug delivery system market 2022 – Industry Growth by 2035

    Roots Analysis has announced the addition of “Non-Viral Drug Delivery Systems Market: Focus on Intracellular Technologies and Biologics (2nd Edition), 2022-2035” report to its list of offerings.

    Key Market Insights
     Presently, over 90 non-viral drug delivery systems developers are engaged in the healthcare market, located across the globe
     Currently, more than 95 non-viral drug delivery systems are offered by several players in the healthcare domain
     The partnership activity for non-viral drug delivery systems in the healthcare domain has grown at a CAGR of over 40%, in the past three years, 2018-2021
     The projected future opportunity for companies engaged in this field is expected to be well distributed across type of molecule, type of biologic delivered, type of technology, target therapeutic area, type of payment model and key geographical regions.

    Table of Contents

    1. PREFACE
    1.1. Scope of the Report
    1.2. Research Methodology
    1.3. Market Segmentations
    1.4. Key Questions Answered
    1.5. Chapter Outlines

    2. EXECUTIVE SUMMARY

    3. INTRODUCTION
    3.1. Chapter Overview
    3.2. Need for Targeted Drug Delivery
    3.3. Advanced Approaches for Delivery of Drug Payloads
    3.3.1. Nanoparticle Delivery Systems
    3.3.1.1. Liposomes
    3.3.1.2. Nanoparticles / Microparticles
    3.3.1.3. PEGylation
    3.3.1.4. Cell Penetrating Peptides (CPPs)
    3.3.2. Other Drug Delivery Technologies
    3.4. Future Perspectives

    4. MARKET LANDSCAPE
    4.1. Chapter Overview
    4.2. Intracellular Drug Delivery: List of Technologies
    4.2.1. Analysis by Type of Molecule Delivered
    4.2.2. Analysis by Type of Biologic Delivered
    4.2.3. Analysis by Type of Interaction
    4.2.4. Analysis by Therapeutic Portfolio
    4.3. Intracellular Drug Delivery: List of Technology Developers
    4.3.1. Analysis by Year of Establishment
    4.3.2. Analysis by Company Size
    4.3.3. Analysis by Type of Company
    4.3.4. Analysis by Location of Headquarters (By Region)

    5. KEY INSIGHTS
    5.1. Chapter Overview
    5.2. Analysis by Type of Technology
    5.3. Analysis by Company Size and Type of Molecule Delivered
    5.4. Analysis by Location of Headquarters (Region-wise) and Type of Service Provider
    5.5. Analysis by Company Size and Location of Headquarters

    6. COMPANY COMPETITIVENESS ANALYSIS
    6.1. Chapter Overview
    6.2. Assumptions / Key Parameters
    6.3. Methodology
    6.4. Company Competitiveness Analysis: Benchmarking of Portfolio Strength
    6.5. Company Competitiveness Analysis: Benchmarking of Partnership Strength
    6.5.1. Company Competitiveness Analysis: Very Small Companies
    6.5.2. Company Competitiveness Analysis: Small Companies
    6.5.3. Company Competitiveness Analysis: Mid-Sized Companies
    6.5.4. Company Competitiveness Analysis: Large and Very Large Companies

    7. COMPANY PROFILES
    7.1. Arcturus Therapeutics
    7.2. Bio-Path
    7.3. CureVac
    7.4. Entos Pharmaceuticals
    7.5. eTheRNA immunotherapies
    7.6. Matinas BioPharma
    7.7. MDimune
    7.8. PCI Biotech

    8. PATENT ANALYSIS
    8.1. Chapter Overview
    8.2. Scope and Methodology
    8.3. Intracellular Drug Delivery Technologies: Patent Analysis
    8.3.1. Analysis by Type of Patent
    8.3.2. Analysis by Publication Year
    8.3.3. Analysis by Application Year
    8.3.4. Analysis by Cumulative Number of Granted Patents
    8.3.5. Analysis by Cumulative Number of Patent Applications
    8.3.6. Analysis by Issuing Authority
    8.3.7. Analysis by Type of Player
    8.3.8. Leading Players: Analysis by Number of Patents
    8.3.9. Leading Inventors: Analysis by Number of Patents
    8.3.10. Analysis by Top Sections
    8.3.11. Intracellular Drug Delivery Technologies: Patent Benchmarking Analysis
    8.4. Intracellular Drug Delivery Technologies: Patent Valuation Analysis

    9. PARTNERSHIPS AND COLLABORATIONS
    9.1. Chapter Overview
    9.2. Partnership Models
    9.3. Intracellular Drug Delivery Technologies: List of Partnerships and Collaborations
    9.3.1. Cumulative Analysis of Partnerships by Year, 2015-2022
    9.3.2. Analysis by Type of Partnership
    9.3.3. Analysis by Year and Type of Partnership, 2015-2022
    9.3.4. Analysis by Purpose of Partnership
    9.3.5. Analysis by Type of Molecule Delivered
    9.3.6. Analysis by Type of Biologic Delivered
    9.3.7. Analysis by Target Therapeutic Area
    9.3.8 Analysis by Year of Partnership and Type of Payment Model Employed, 2015-2022
    9.3.9. Analysis by Year of Partnership and Type of Company, 2015-2022
    9.3.10. Analysis by Purpose of Partnership and Type of Company
    9.3.11. Most Active Players: Analysis by Number of Partnerships
    9.3.12. Most Popular Technologies: Analysis by Number of Partnerships
    9.3.13. Analysis by Region
    9.3.14. Local and International Agreements
    9.3.15. Intracontinental and Intercontinental Agreements

    10. OPPORTUNITY ASSESSMENT FRAMEWORK: KALBACH INNOVATION MODEL, COMPETITVE ASSESSMENT FRAMEWORK AND BCG MATRIX
    10.1. Chapter Overview
    10.2. Kalbach Innovation Model
    10.2.1. Key Assumptions and Methodology
    10.2.2. Analysis by Trends in Research Activity
    10.2.3. Analysis by Trends in Investment Activity
    10.2.4. Analysis by Trends in Partnership Activity
    10.2.5. Analysis by Number of Technologies
    10.2.6. Analysis by Trends in Deal Amount
    10.2.7. Analysis by Number of Google Hits
    10.2.8. Qualitative and Quantitative Assessment based on Secondary and Primary Research
    10.2.9. Kalbach Innovation Model: Output Analysis

    10.3. Competitive Assessment Framework
    10.3.1. Key Assumptions and Methodology
    10.3.2. Competitive Assessment Framework: Output Analysis

    10.4. BCG Matrix
    10.4.1. Key Assumptions and Methodology
    10.4.2. BCG Matrix: Output Analysis

    11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
    11.1. Chapter Overview
    11.2. Key Assumptions
    11.3. Forecast Methodology
    11.4. Global Non-Viral Intracellular Drug Delivery Technologies Market, 2022-2035
    11.5. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Payment Model Employed, 2022 and 2035
    11.5.1 Non-Viral Intracellular Drug Delivery Technologies Market for Milestone Payments, 2022-2035
    11.5.2 Non-Viral Intracellular Drug Delivery Technologies Market for Upfront Payments, 2022-2035
    11.6. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Molecule Delivered, 2022 and 2035
    11.6.1 Non-Viral Intracellular Drug Delivery Technologies Market for Biologics, 2022-2035
    11.6.2 Non-Viral Intracellular Drug Delivery Technologies Market for Small Molecules, 2022-2035
    11.7. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Biologic Delivered, 2022 and 2035
    11.7.1 Non-Viral Intracellular Drug Delivery Technologies Market for RNA, 2022-2035
    11.7.2 Non-Viral Intracellular Drug Delivery Technologies Market for DNA, 2022-2035
    11.7.3 Non-Viral Intracellular Drug Delivery Technologies Market for Proteins / Peptides, 2022-2035
    11.7.4 Non-Viral Intracellular Drug Delivery Technologies Market for Antibodies, 2022-2035
    11.8. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Technology, 2022 and 2035
    11.8.1. Non-Viral Intracellular Drug Delivery Technologies Market for Nanoparticles, 2022-2035
    11.8.2 Non-Viral Intracellular Drug Delivery Technologies Market for Extracellular Vesicles, 2022-2035
    11.8.3 Non-Viral Intracellular Drug Delivery Technologies Market for Polymers, 2022-2035
    11.8.4 Non-Viral Intracellular Drug Delivery Technologies Market for Oligonucleotides, 2022-2035
    11.8.5 Non-Viral Intracellular Drug Delivery Technologies Market for Cell Penetrating Peptides, 2022-2035
    11.9. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Target Therapeutic Areas, 2022 and 2035
    11.9.1 Non-Viral Intracellular Drug Delivery Technologies Market for Infectious Diseases, 2022-2035
    11.9.2 Non-Viral Intracellular Drug Delivery Technologies Market for Oncological Disorders, 2022-2035
    11.9.3 Non-Viral Intracellular Drug Delivery Technologies Market for Genetic Disorders, 2022-2035
    11.9.4 Non-Viral Intracellular Drug Delivery Technologies Market for Cardiovascular Disorders 2022-2035
    11.9.5 Non-Viral Intracellular Drug Delivery Technologies Market for Hepatic Disorders, 2022-2035
    11.9.6 Non-Viral Intracellular Drug Delivery Technologies Market for Neurological Disorders, 2022-2035
    11.9.7 Non-Viral Intracellular Drug Delivery Technologies Market for Other Diseases, 2022-2035
    11.10. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Geography, 2022 and 2035
    11.10.1. Non-Viral Intracellular Drug Delivery Technologies Market in North America, 2022-2035
    11.10.2. Non-Viral Intracellular Drug Delivery Technologies Market in Europe, 2022-2035
    11.10.3. Non-Viral Intracellular Drug Delivery Technologies Market in Asia, 2022-2035
    11.10.4. Non-Viral Intracellular Drug Delivery Technologies Market in Rest of the World, 2022- 2035
    11.10.5. Non-Viral Intracellular Drug Delivery Technologies Market in Middle East and North Africa, 2022-2035
    11.10.6. Non-Viral Intracellular Drug Delivery Technologies Market in Latin America, 2022-2035

    12. CONCLUDING REMARKS

    13. EXECUTIVE INSIGHTS
    13.1. Chapter Overview
    13.2. Biond Biologics
    13.2.1. Interview Transcript: Tehila BenMoshe, Chief Executive Officer and Itay Friedman, Vice President Clinical Development

    13.3. Carmine Therapeutics
    13.3.1. Interview Transcript: Don Haut, Chief Executive Officer

    13.4. Eyevensys
    13.4.1. Interview Transcript: Thierry Bordet, Chief Scientific Officer

    13.5. Generation Bio
    13.5.1. Interview Transcript: Maren Killackey, Senior Director, Investor Relations and Communications

    13.6. PCI Biotech
    13.6.1. Interview Transcript: Anders Høgset, Research Director / Chief Scientific Officer

    13.7. SRI International
    13.7.1. Interview Transcript: Melissa Wagner, Strategic Business Executive, Biosciences Division

    14. APPENDIX 1: TABULATED DATA

    15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

    To view more details on this report, click on the link
    https://www.rootsanalysis.com/reports/non-viral-drug-delivery-systems-market.html


    You may also be interested in the following titles:
    Global Antibiotics Market

    Pharmaceutical Polymers / Medical Polymers Market


    You may also like to learn what our experts are sharing in Roots educational series:
    Advancements in Automation of Processes: Key Value Driver for Escalated Interest in Cell Therapies Manufacturing Domain
    CAR-T Cell Therapies: Addressing Key Unmet Needs Across Various Oncological Indications

    About Roots Analysis
    Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

    Contact:
    Ben Johnson
    +1 (415) 800 3415
    Ben.johnson@rootsanalysis.com



    #nonviraldrugdeliverysystemmarket #nonviraldrugdeliverysystemmarketSize #genedeliverysystems #intracellulardelivery #intracellulardrugdelivery
    Intracellular Drug Delivery Systems Market | Industry Analysis | Market Size | 2035
    Driven by growing demand for effective drug products, the non-viral / intracellular drug delivery technologies market is likely to grow at 13.8% CAGR, till 2035
    WWW.ROOTSANALYSIS.COM
    0 0 Reacties 0 Aandelen

Geen resultaten te tonen

Geen resultaten te tonen

Geen resultaten te tonen

Geen resultaten te tonen

Geen resultaten te tonen